Blog
151 Articles
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
From Dismissal to Diagnosis
Elizabeth Rountree’s first doctor dismissed her symptoms of itchiness and abdominal discomfort, but her gastroenterologist listened and ordered important tests.
Large Clinical Trial For Cachexia Treatment
Lead investigator Dr. Jeffrey Crawford reports on the positive results from a cachexia clinical trial of a new immunotherapy drug to treat the condition.
(Currently) Incurable, (Continuously) Fighting
Katie DeCarlo is continuously fighting her PNET. She is determined to try and will continue to try as many types of treatment as possible
FDA Approves Tumor Treating Fields For Locally Advanced Disease
Dr. Vincent Picozzi explains how the recently approved tumor treating fields device is changing the game for pancreatic cancer patients.
Pancreatic Cancer at Any Age
Long-term survivor Ryan Dwars was diagnosed at age 36, with young children, but he has been determined to be an outlier.
Novel Oral Drug Shows Promise
Dr. Barbara Ma provides context for the nine-month data on a clinical trial of the novel drug atebimetinib and standard chemo.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
Fleeting, Fragile, and Funny
Eric Egelman had molecular profiling of his tumor and a KRAS mutation was found. This qualified him for a vaccine clinical trial.
“Off-the-Shelf” Vaccine Improves Overall and Average Relapse Survival
Dr. Zev Wainberg provides an update on the effectiveness of a vaccine, with results showing it extends the time to relapse in many patients.
Three Buckets
Long-term survivor Bob Minetti worked as a fundraiser at a major cancer center, so he challenged the doctors to show how good they were.
New Pain Control Technology for Locally Advanced Pancreatic Cancer
Dr. Hani Babiker outlines the results of the PANOVA-3 trial, which tested Tumor Treating Fields and chemotherapy for pain control.